Can a smart gel regrow jawbone after tooth extraction?

NCT ID NCT07779421

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study is testing whether a special gel, made from a temperature-sensitive material and loaded with growth factors, can help the jawbone heal and regenerate after impacted wisdom teeth are removed. The gel is liquid when stored cold but turns into a gel at body temperature, designed to fill the empty socket and encourage bone growth. Researchers will compare healing, bone width and height, pain, swelling, and other outcomes in people who receive this gel versus those who do not. The goal is to see if this approach can reduce bone loss and improve recovery after this common dental procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A temperature-sensitive gel made from hydroxybutyl chitosan and loaded with concentrated growth factors, applied to the extraction site to support bone healing and regeneration.
What this could lead to
If successful, this gel could offer a simple way to preserve jawbone and reduce complications after wisdom tooth removal, potentially improving dental health and reducing the need for future bone grafts.
What could go wrong
This is a real-world study, not a controlled trial, so results may be less definitive. The gel's effectiveness and safety are still being tested, and individual outcomes may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: * Preoperative CBCT imaging confirming mandibular third molars (M3s) with low to moderate impaction according to the Pell and Gregory classification, and not in the acute inflammatory stage. * Ipsilateral mandibular second molars (M2s) with retention value and no indication for extraction. * Patients able to provide written informed consent and willing to comply with the scheduled follow-up visits. * Age between 18 and 60 years (inclusive). * Exclusion Criteria: * Presence of systemic diseases or other contraindications to tooth extraction surgery. * Known or suspected current malignancy. * History of radiation therapy to the head and neck region. * History of chemotherapy within 5 years prior to surgery. * Smoking \> 15 cigarettes per day. * Subjects with mental or neurological disorders, or otherwise unable to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone loss are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss periodontal disorder Tooth, Impacted

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stomatological Hospital Affiliated with Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.